New treatment strategy tested for aggressive blood cancer in younger patients
NCT ID NCT02858804
Summary
This study tested two different chemotherapy combinations, with or without the drug rituximab, to treat younger patients (age 65 or under) newly diagnosed with mantle cell lymphoma, a type of blood cancer. It aimed to see which approach was better at controlling the disease and keeping it from coming back. After initial treatment, patients could also receive different maintenance therapies to help sustain the results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shuhua Yi
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.